← Back to Search

Tyrosine Kinase Inhibitor

Pembrolizumab for Solid Tumors

Phase 2
Waitlist Available
Led By Nancy Wang, MD, MPH
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must have histologically or cytologically confirmed solid malignancy.
Absolute neutrophil count (ANC) ≥1500/μL
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 months
Awards & highlights

Study Summary

This trial will test to see if the experimental drug combination can help improve the survival rate for people with Leptomeningeal Metastases.

Eligible Conditions
  • Solid Tumors
  • Leptomeningeal Metastasis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of Participants alive at 6 months
Secondary outcome measures
Extracranial Progression Free Survival (EPFS)
Intracranial/intraspinal Progression Free Survival (IPFS)
Median Extracranial Progression Free Survival (EPFS)
+7 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Kidney Injury and/or Infection
7%
Pneumonia
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Activated partial thromboplastin time prolonged
5%
Intractable pain, back pain, hip pain
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Skin rash
2%
Thrombocytopenia
2%
Respiratory failure
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: PEMBROLIZUMAB and LENVATINIBExperimental Treatment2 Interventions
The research study procedures include screening for eligibility and study treatment, including evaluations and follow up visits. PEMBROLIZUMAB daily, every 3 weeks LENVATINIB daily every 3 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved
Lenvatinib
FDA approved

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,918 Previous Clinical Trials
13,192,825 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,862 Previous Clinical Trials
5,049,690 Total Patients Enrolled
Nancy Wang, MD, MPHPrincipal InvestigatorMassachusetts General Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the most common reasons that doctors prescribe Pembrolizumab?

"Pembrolizumab is most commonly used to fight cancer, but it can be employed in the treatment of other conditions such as microsatellite instability high and disease progression after chemotherapy."

Answered by AI

Are there long-term negative effects to Pembrolizumab treatment?

"While there is some evidence that Pembrolizumab is safe for human consumption, it only received a score of 2 because this is still a Phase 2 trial and there is no data supporting efficacy."

Answered by AI

Are there any slots available for new patients in this trial?

"The most recent information from clinicaltrials.gov suggests that this trial is still actively recruiting patients. The listing for the trial was first posted on March 8th, 2021 and updated September 22nd, 2021."

Answered by AI

How many people can join this particular clinical trial?

"The most recent information on clinicaltrials.gov suggests that this trial is still looking for subjects. The study was originally posted on March 8th, 2021 and has been edited as recently as September 22nd, 2021. They need 19 patients from 2 different locations."

Answered by AI

What is the research history of Pembrolizumab?

"Pembrolizumab is being trialed in 1076 active studies, 134 of which are in Phase 3. While some trials for Pembrolizumab are taking place in Sacramento, California, this medication is being tested in 37366 different locations globally."

Answered by AI
~2 spots leftby Mar 2025